scholarly journals ALKBH overexpression in head and neck cancer: potential target for novel anticancer therapy

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Tomaš Pilžys ◽  
Michał Marcinkowski ◽  
Wojciech Kukwa ◽  
Damian Garbicz ◽  
Małgorzata Dylewska ◽  
...  
Keyword(s):  
Head And Neck ◽  
Anticancer Therapy ◽  
Squamous Cell Carcinomas ◽  
High Expression ◽  
Cytoplasmic Localization ◽  
Biological Functions ◽  
Substrate Specificities ◽  
Cancerous Cell ◽  
Anthraquinone Derivatives ◽  
Combined Overexpression

Abstract The nine identified human homologues of E. coli AlkB 2-oxoglutarate (2OG) and Fe(II)-dependent dioxygenase, ALKBH1-8 and FTO, display different substrate specificities and diverse biological functions. Here we discovered the combined overexpression of members of the ALKBH family in head and neck squamous cell carcinomas (HNSCC). We found direct correlation of ALKBH3 and FTO expression with primary HNSCC tumor size. We observed unidentified thus far cytoplasmic localization of ALKBH2 and 5 in HNSCC, suggesting abnormal role(s) of ALKBH proteins in cancer. Further, high expression of ALKBHs was observed not only in HNSCC, but also in several cancerous cell lines and silencing ALKBH expression in HeLa cancer cells resulted in dramatically decreased survival. Considering the discovered impact of high expression of ALKBH proteins on HNSCC development, we screened for ALKBH blockers among newly synthetized anthraquinone derivatives and demonstrated their potential to support standard anticancer therapy.

The clinicopathological significances and biological functions of parafibromin expression in head and neck squamous cell carcinomas

Tumor Biology ◽  
2015 ◽  
Vol 36 (12) ◽  
pp. 9487-9497 ◽  
Author(s):  
Zhuo Zhang ◽  
Xue-feng Yang ◽  
Ke-qiang Huang ◽  
Li Ren ◽  
Wen-feng Gou ◽  
...  
Keyword(s):  
Head And Neck ◽  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
Biological Functions

scholarly journals High expression of oxidative phosphorylation genes predicts improved survival in squamous cell carcinomas of the head and neck and lung

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Mitchell Frederick ◽  
Heath D. Skinner ◽  
Sawad A. Kazi ◽  
Andrew G. Sikora ◽  
Vlad C. Sandulache
Keyword(s):  
Oxidative Phosphorylation ◽  
Head And Neck ◽  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
High Expression

Smoking correlates with the presence of p53 mutations in squamous cell carcinomas of the head and neck (SCCHN)

1998 ◽  
Vol 23 (3) ◽  
pp. 268-269
Author(s):  
Liloglou ◽  
Scholes ◽  
Spandidos ◽  
Jones ◽  
Vaughan ◽  
...  
Keyword(s):  
Head And Neck ◽  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
P53 Mutations

Identification of the Genomic Structure of Tumor Suppressor ING1 and Mutation Analysis in Head and Neck Squamous Cell Carcinomas

2005 ◽  
Vol 14 (2) ◽  
pp. 320-321
Author(s):  
Mehmet Gunduz ◽  
Esra Gunduz ◽  
Byung-Moo Min ◽  
Gene Lee ◽  
Ji-Jun Lim ◽  
...  
Keyword(s):  
Tumor Suppressor ◽  
Head And Neck ◽  
Mutation Analysis ◽  
Squamous Cell ◽  
Genomic Structure ◽  
Squamous Cell Carcinomas

O53. Multicenter validation of a lymph node metastasis gene expression signature for head and neck squamous cell carcinomas

Oral Oncology ◽  
2011 ◽  
Vol 47 ◽  
pp. S46
Author(s):  
F.K.J. Leusink ◽  
P.J. Slootweg ◽  
M.W.M. van den Brekel ◽  
R.J. Baatenburg de Jong ◽  
F.C.P. Holstege ◽  
...  
Keyword(s):  
Gene Expression ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Head And Neck ◽  
Squamous Cell ◽  
Gene Expression Signature ◽  
Squamous Cell Carcinomas ◽  
Expression Signature ◽  
Node Metastasis ◽  
Multicenter Validation

Long-Term Follow-up on an Intensified Treatment Regimen for Advanced Resectable Head and Neck Squamous Cell Carcinomas

2001 ◽  
Vol 19 (2) ◽  
pp. 127-136 ◽  
Author(s):  
John C. Grecula ◽  
David E. Schuller ◽  
Roy Smith ◽  
Chris A. Rhoades ◽  
Subir Nag ◽  
...  
Keyword(s):  
Head And Neck ◽  
Treatment Regimen ◽  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
Long Term Follow Up

Fever range whole body hyperthermia for re-irradiation of head and neck squamous cell carcinomas: Final results of a prospective study

Oral Oncology ◽  
2021 ◽  
Vol 116 ◽  
pp. 105240
Author(s):  
Sebastian Zschaeck ◽  
Julian Weingärtner ◽  
Pirus Ghadjar ◽  
Peter Wust ◽  
Felix Mehrhof ◽  
...  
Keyword(s):  
Prospective Study ◽  
Head And Neck ◽  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
Whole Body ◽  
Whole Body Hyperthermia ◽  
A Prospective Study

Utilization of P16 in Head and Neck Cytology and Surgical Specimens After the Release of CAP Guidelines

2020 ◽  
Vol 154 (Supplement_1) ◽  
pp. S22-S22
Author(s):  
H Laharwani ◽  
V Manucha ◽  
G Jefferson ◽  
L Jackson
Keyword(s):  
Head And Neck ◽  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
Common Reason ◽  
Unknown Primary ◽  
Hpv Testing ◽  
Neck Masses ◽  
P16 Immunohistochemistry ◽  
Hpv Status ◽  
Wrong Site

Abstract Introduction/Objective HPV-positive oropharyngeal squamous cell carcinoma is biologically and clinically unique and has a survival advantage over other head and neck squamous cell carcinomas. In December 2017 College of American Pathologist published guidelines for testing HPV status in head and neck cancer. It was recommended that pathologists perform HR-HPV testing on head and neck squamous cell carcinomas from all patients with known oropharyngeal SCC not previously tested for HR-HPV, with suspected oropharyngeal SCC, or with metastatic SCC of unknown primary. The aim of this study was to determine the compliance of pathologists following the CAP guidelines. Methods Cases that underwent HPV testing using p16 immunohistochemistry for the years 2017 and 2019 were retrieved. Based on the guidelines, p16 testing was designated as “indicated” or “not indicated”. Results There were 196 cases in which p16 testing was performed in a period of 3 consecutive years. Of these, 175 were FNA/ biopsies and 21 were surgical resections. In 69 cases (56 FNAs and 13 biopsies) the biopsy was performed on neck masses with unknown primary. The compliance for p16 testing in OPC and Lymph nodes with metastatic SCC of unknown primary was 100%. In 34 (17.3%) cases p16 testing was not indicated, the most common reason being wrong site (85%) including the larynx, oral tongue, the floor of the mouth, buccal mucosa, and nasal mass. Of the unindicated p16s, 20 (58%) were received in consultation for continuity of care. Conclusion Not being clear about the site of the tumor is the most common reason for unindicated p16 testing. A clear designation of biopsy site and proper communication between pathologist and surgeon can improve utilization of p16 testing in head and neck carcinomas.

Sign in / Sign up

Export Citation Format

Share Document